Developments with investigational Janus kinase inhibitors for rheumatoid arthritis

Expert Opin Investig Drugs. 2016 Dec;25(12):1355-1359. doi: 10.1080/13543784.2016.1249565. Epub 2016 Oct 31.

Authors

Luca Semerano^{1

2

3}, Patrice Decker^{1

2}, Gaëlle Clavel^{2

4}, Marie-Christophe Boissier^{1

2

3}

Affiliations

¹ a Inserm UMR 1125 , Bobigny , France.
² b Sorbonne Paris Cité , Université Paris 13 , Bobigny , France.
³ c Department of Rheumatology , Hôpitaux Universitaires Paris-Seine-Saint Denis, Assistance-Publique-Hôpitaux de Paris (APHP) , Bobigny , France.
⁴ d Department of Internal Medicine , Fondation Rothschild , Paris , France.

PMID: 27748152
DOI: 10.1080/13543784.2016.1249565

No abstract available

Keywords: ABT-494; Rheumatoid arthritis; baricitinib; decernotinib; filgotinib; janus kinases; peficitinib; tofacitinib.

Publication types

Editorial

MeSH terms

Antirheumatic Agents / pharmacology
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / enzymology
Arthritis, Rheumatoid / physiopathology
Drug Design
Humans
Janus Kinases / antagonists & inhibitors*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Antirheumatic Agents
Protein Kinase Inhibitors
Janus Kinases